Abstract:Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to reduce cardiovascular events. However, their effects on intracranial atherosclerotic plaque remain elusive. The prospective study aims to investigate the effect of adding PCSK9 inhibition to statin therapy on intracranial atherosclerotic plaque features in those ischemic stroke patients with severe intracranial atherosclerotic stenosis (ICAS) using high-resolution vessel wall magnetic resonance imaging (HRVW-MRI). Methods: In our single-center study, a total of 29 patients with high-grade ICAS (PCSK9i group, n=19; control group, n=10) were included. HRVW-MRI scans at baseline and 3-6 months posttreatment were performed. The clinical characteristics and plaque features including plaque area, plaque burden, enhancement ratio, eccentricity, percent wall volume (PWV) and degree of stenosis were investigated. Results: Compared with statin monotherapy, the least-squares mean percentage reduction low-density lipoprotein cholesterol (LDL-C) with PCSK9 inhibitor add-on therapy was 71% at 1 month, 69% at 3 months and 64% at 6 months (p<0.001 for all comparisons). Fifteen patients (51.7%) completed HRVW-MRI at both baseline and follow-up. A significant reduction in plaque enhancement ratio (-13.7%, 95% CI, -27.2% to 0.3%) and degree of stenosis (-11.7%, 95% CI, -23.3% to -0.1%) was observed in PCSK9i group but not in control group (37.7%, 95% CI, -14.6% to 221%, p=0.024 and 16.0%, 95% CI, -7.6% to 39.6%, p=0.027, respectively). The plaque area, plaque burden, eccentricity and PWV did not change significantly during the follow-up. Among those patients, the median follow-up duration was 11 months (IQR, 9-14), most (28/29, 96.6%) did not suffer from stroke during the follow-up, with no statistical difference in median National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) scores between the groups. Conclusion: Inhibition of PCSK9 added to high-intensity statin therapy can lower the LDL-C levels, slow down the progression of stenosis and stabilize plaque in patients with severe ICAS. These findings provide insight into the benefit of lowering LDL-C levels below current recommendation targets with the PCSK9 inhibitor add-on therapy in patients with high-grade ICAS. Trial registration: Clinicaltrial.gov, NCT04847752, registered April 19, 2021, https://www.clinicaltrials.gov/ct2/show/NCT04847752.

Cerebral Blood Flow Evaluation of Intensive Rosuvastatin Therapy in Stroke/Transient Ischemic Attack Patients with Intracranial Arterial Atherosclerotic Stenosis Study: Rationale and Design

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study

Evaluation of the effect of atorvastatin on neovascularization in the carotid atherosclerotic plaques by contrast enhanced ultrasonography

Design of the "EAST" strategy in patients with asymptomatic intracranial atherosclerotic stenosis

Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.

Improving effects of rosuvastatin calcium on atherosclerosis and cerebral blood flow dynamics in patients with cerebral infarction

A single-center pilot randomized controlled trial of atorvastatin loading for preventing ischemic brain damage after carotid artery stenting

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

PCSK9 Inhibitor with Statin Therapy for Intracranial Artery Stenosis ( PISTIAS): Rationale and design of a multicenter randomized controlled trial

Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study

PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging

Hemodynamic Change of Coronary Atherosclerotic Plaque after Statin Treatment: A Serial Follow‐Up Study by Computed Tomography‐Derived Fractional Flow Reserve

Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)

Effects of intracranial artery stenosis of anterior circulation on cognition-A CT perfusion-based study

Intensive Statin Treatment in Acute Ischaemic Stroke Patients with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study)

Effect of Remote Ischemic Preconditioning on Cerebral Circulation Time in Severe Carotid Artery Stenosis: Results from the RIC-CCT Trial

Remote ischemic conditioning improves cerebral hemodynamics in symptomatic intracranial atherosclerosis: A PET/CT‐guided randomized controlled study

Comparison of Cilostazol Versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke Who Underwent Intracranial or Extracranial Artery Stent Implantation

A clinical application study of a stent placement assessment

PCSK9 Inhibition Reduces Low-Density Lipoprotein Cholesterol and Stabilizes the Plaque in Ischemic Stroke Patients with Severe Intracranial Atherosclerotic Stenosis

Design of stroke imaging package study of intracranial atherosclerosis: a multicenter, prospective, cohort study